CEOP-R regimen: Difference between revisions

	WikiDoc Resources for CEOP-R regimen
Articles
Most recent articles on CEOP-R regimen Most cited articles on CEOP-R regimen Review articles on CEOP-R regimen Articles on CEOP-R regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on CEOP-R regimen Images of CEOP-R regimen Photos of CEOP-R regimen Podcasts & MP3s on CEOP-R regimen Videos on CEOP-R regimen
Evidence Based Medicine
Cochrane Collaboration on CEOP-R regimen Bandolier on CEOP-R regimen TRIP on CEOP-R regimen
Clinical Trials
Ongoing Trials on CEOP-R regimen at Clinical Trials.gov Trial results on CEOP-R regimen Clinical Trials on CEOP-R regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on CEOP-R regimen NICE Guidance on CEOP-R regimen NHS PRODIGY Guidance FDA on CEOP-R regimen CDC on CEOP-R regimen
Books
Books on CEOP-R regimen
News
CEOP-R regimen in the news Be alerted to news on CEOP-R regimen News trends on CEOP-R regimen
Commentary
Blogs on CEOP-R regimen
Definitions
Definitions of CEOP-R regimen
Patient Resources / Community
Patient resources on CEOP-R regimen Discussion groups on CEOP-R regimen Patient Handouts on CEOP-R regimen Directions to Hospitals Treating CEOP-R regimen Risk calculators and risk factors for CEOP-R regimen
Healthcare Provider Resources
Symptoms of CEOP-R regimen Causes & Risk Factors for CEOP-R regimen Diagnostic studies for CEOP-R regimen Treatment of CEOP-R regimen
Continuing Medical Education (CME)
CME Programs on CEOP-R regimen
International
CEOP-R regimen en Espanol CEOP-R regimen en Francais
Business
CEOP-R regimen in the Marketplace Patents on CEOP-R regimen
Experimental / Informatics
List of terms related to CEOP-R regimen

VisualWikitext

Revision as of 13:48, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Cyclophosphamide/Epirubicin/Vincristine/Prednisone

Overview

CEOP-R regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, epirubicin, vincristine (Oncovin), prednisone and rituximab used to treat both indolent and aggressive forms of Diffuse large B-cell lymphoma.^[1]

Regimen

C – Cyclophosphamide

E – Epirubicin

O – Vincristine (Oncovin)

P – Prednisone

R – Rituximab

Indications

Diffuse large B-cell lymphoma^[1]

References

↑ ^1.0 ^1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.

[pmid24258714-1] 1.0 ^1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.

[1]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AV}}
-{{SK}} CEOP Regimen; Cyclophosphamide/Epirubicin/Vincristine/Prednisone
+{{SK}} Cyclophosphamide/Epirubicin/Vincristine/Prednisone
 ==Overview==